Log in to search using one of your social media accounts:

 

Inhibition OF USP7 Induces Selective Cancer Cell Death in Chronic Lymphocytic Leukemia
CLL is a lymphoproliferative disorder with indolent clinical course. Beside standard chemoimmunotherapy, higher risk subgroups -namely those harboring TP53 mutations or deletions of the short arm of chromosome 17 (del17p)- may benefit from newer targeted drugs which act downstream of the B cell receptor. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Giovanna Carr à, Cristina Panuzzo, Davide Torti, Guido Parvis, Sabrina Crivellaro, Marco Volante, Deborah Morena, Marcello Lingua, Mara Brancaccio, Angelo Guerrasio, Pier Paolo Pandolfi, Giuseppe Saglio, Riccardo Taulli, Alessandro Morotti Source Type: research

Non-Oncogene Addiction to BRD in CLL: from JQ1 Response to Resistence
Despite significant advances in the molecular characterization of Chronic Lymphocytic Leukemia (CLL), CLL remains basically incurable and patients generally relapse after an initial response to standard care treatments, principally consisting in immuno-chemotherapy regimens. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Giovanna Carr à, Sabrina Crivellaro, Cristina Panuzzo, Deborah Morena, Marcello Lingua, Giuseppe Saglio, Riccardo Taulli, Alessandro Morotti Source Type: research

Venetoclax Plus Rituximab can Achieve Durable Treatment-Free Remission in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Venetoclax (VEN) is a selective, potent, orally bioavailable BCL-2 inhibitor. VEN in combination with rituximab (R) is being assessed in an ongoing Phase 1b study. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Michael Choi, Danielle Brander, Andrew W. Roberts, John F. Seymour, Thomas J. Kipps, Jacqueline C. Barrientos, Matthew S. Davids, Mary Ann Anderson, Constantine Tam, Betty Prine, Carmen Cornejo, Ming Zhu, Leanne Lash, Su Young Kim, Shuo Ma Source Type: research

Cross-Study Multivariable Analysis of the Impact of Adding Rituximab to Venetoclax on the Depth and Durability of Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Venetoclax (VEN) is a selective, potent, orally bioavailable BCL-2 inhibitor that induced high overall response rates (ORR, 79%) and complete responses (CR, 20%) in a first-in-human dose escalation study (M12-175) in patients with relapsed/refractory (R/R) CLL. The addition of monthly rituximab (R; months 1 –6) in combination with VEN is being evaluated in an ongoing phase 1b dose-escalation study (M13-365) and as of 28 Oct 2015, the observed ORR is 86% and the CR rate is 47%. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Constantine Tam, Andrew W. Roberts, Shuo Ma, Danielle Brander, Thomas J. Kipps, Jacqueline C. Barrientos, Matthew S. Davids, Mary Ann Anderson, Michael Choi, Leanne Lash, Maria Verdugo, Su Young Kim, Ming Zhu, John F. Seymour Source Type: research

Ventricular Arrhythmias and Sudden Death in Patients Taking Ibrutinib
Ibrutinib is a small molecule BTK inhibitor that has become a first- or second-line therapy for many patients with CLL and mantle cell lymphoma, but causes atrial fibrillation in approximately 6-9% of patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Benjamin Lampson, Lijian Yu, Jacqueline Barrientos, Eric Jacobsen, Versha Banerji, Jeffrey Jones, Kerry Savage, Renata Walewska, Javid Moslehi, Jennifer Brown Source Type: research

From Human Genetic to Mouse Model: SF3B1 Mutation and its Impact on Chronic Lymphocytic Leukemia
Large-scale sequencing studies using primary samples have identified SF3B1 as among the most frequently mutated genes in chronic lymphocytic leukemia (CLL). These mutations localize to a restricted gene region, with more than 50% at the K700E site. They co-occur at high frequency with ATM mutations and deletion of chromosome 11, whose minimally deleted region contains ATM. While SF3B1 mutations have been associated with adverse clinical outcome in CLL, mechanistic understanding of its role in the oncogenic phenotype is lacking. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Lili Wang, Angela Brooks, Rutendo Gambe, Jean Fan, Jing Sun, Sarah Hergert, Youzhong Wan, Donna Neuberg, Peter Kharchenko, Matthew Meyerson, Mark Fleming, Benjamin Ebert, Catherine Wu Source Type: research

Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in General Community: a Single-Center Experience
Ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase (BTK), is a novel drug which has shown significant efficacy and survival benefit for treatment of various B-cell malignancies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Naveed Ali, Syed Imran Mustafa Jafri, Faizan Malik, Mark Sundermeyer, Peter Pickens Source Type: research

Imatinib Mesylate as First-line Therapy in Patients with Chronic Myeloid Leukemia Philadelphia + (CML-PH+) in Accelerated Phase (AP), Comparison with Chronic Phase. A Long Term Retrospective Study
Accelerated phase (AP), is a progression state of CML. Treatment options varies; however in our institution, Imatinib Mesylate [(IM) Glivec ® Novartis, Mexico] is the only first line treatment avilable and the long-term outcome information is scarce in comparation with Chronic Phase (CP) CML (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Berenice Vicente-Hernandez, Rafael Hurtado-Monroy, Diego Sarre-Alvarez, Pablo Vargas-Viveros, Montserrat Rojas, Carlos Best, Judith Cruz-Vazquez, Myrna Candelaria-Hernandez Tags: Chronic Myelogenous Leukemia Source Type: research

Microsatellite Instability in Chronic Myeloid Leukemia Using D17S261 and D3S643 Markers- a Pilot Study in Western India
This study highlights the possibility of co-existence of microsatellite instability and chromosomal instability in samples with CML confirmed by t(9;22). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Trupti Patel, Manali Chakraborty, Priyanjali Bhattacharya Source Type: research

Real-Life Discontinuation of TKIS
About 60% patients with CML in deep persistent molecular remission (MR4, MR4.5 or MR5), relapse after TKI discontinuation. Here we reported our real-life single center experience. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Debora Luzi Source Type: research

RT-qPCR and RT-Digital PCR: a Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukaemia
Tyrosine Kinase Inhibitors (TKIs) are part of the successful clinical management of patients with Chronic Myeloid Leukaemia (CML). However, optimal clinical management of CML requires a robust, standardized laboratory assay used at key clinical milestones to ensure a successful outcome for patients on TKIs. Quantitative monitoring of %BCR-ABL1IS by reverse transcription quantitative PCR (RT-qPCR) is the gold standard strategy for evaluating patient repose to therapy and classification into prognostic subgroups. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Mary Alikian, Alexandra Whale, Susanna Akiki, Kim Piechocki, Celia Torrado, Thet Myint, Simon Cowen, Michael Griffiths, Jane Apperley, Helen White, Jim F. Huggett, Letizia Foroni Source Type: research

4-Year Results from the Pivotal Phase 2 PACE Trial: Efficacy and Safety in Heavily Pretreated Leukemia Patients
Ponatinib, an approved tyrosine kinase inhibitor, is potently active against native and resistant BCR-ABL, including BCR-ABL1T315I. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Jorge Cortes, Javier Pinilla-Ibarz, Philipp le Coutre, Ronald Paquette, Charles Chuah, Franck Nicolini, Jane Apperley, H. Jean Khoury, Moshe Talpaz, Michele Baccarani, Stephanie Lustgarten, Frank G. Haluska, Fran çois Guilhot, Michael W. Deininger, Andre Source Type: research

A Chart Review of Lower Dosing of Ponatinib in Patients with Chronic Myeloid Leukemia (CML): Preliminary Findings
Ponatinib is approved for adults with refractory CML or Ph+ ALL and those with the T315I mutation. Recommended starting dose is 45 mg/day. Post hoc dose-response analyses from the registrational PACE trial suggest lower doses may mitigate safety risk while maintaining response; outcomes with lower doses have not been evaluated in clinical practice. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Michael Mauro, Lisa McGarry, Ani Inguilizian, Ruth du Moulin, Hui Huang Source Type: research

The PACE Clinical Trial vs The Real-World: Comparison of Ponatinib Prescribing and Duration of Therapy in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients
The efficacy of ponatinib in refractory CP-CML was demonstrated in the pivotal phase 2 PACE trial (NCT01207440). Introduced in the US in December 2012, ponatinib was reintroduced in January 2014 after an 11-week withdrawal to review data on arterial occlusive events, revise US prescribing information, and institute a REMS program. In the US, ponatinib is exclusively distributed by Biologics, Inc., a specialty pharmacy that has maintained prescribing data since Jan 2014. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Michael Mauro, Lisa McGarry, Mo Yang, Stephanie Lustgarten, Hui Huang Source Type: research

Ponatinib versus Bosutinib in 3rd-Line Chronic Phase - Chronic Myeloid Leukemia (CP-CML): Indirect Comparison of Efficacy Using Iterative Proportional Fitting
Open-label trials of ponatinib (PACE, NCT01207440) and bosutinib (NCT00261846; published by Khoury 2012) in third-line patients with CP-CML suggest that ponatinib is more efficacious than bosutinib in this setting, but clinical and reimbursement decisions call for data from head-to-head trials. As such studies are unlikely, we indirectly compared efficacy in the two trials using Iterative Proportional Fitting (IPF) to adjust for differences in baseline characteristics. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Lisa McGarry, Mo Yang, Silvia Chiroli, Stephanie Lustgarten, David Dorer Source Type: research

The OPTIC Study: a Multi-Center, Randomized Phase 2 Trial with Response-Based Dose Reduction to Evaluate Three Starting Doses of Ponatinib
The initial approval of ponatinib (45 mg daily), a potent BCR-ABL tyrosine kinase inhibitor (TKI), for treatment of patients with refractory chronic myeloid leukemia (CML) or Philadelphia-positive acute lymphoblastic leukemia was based on the pivotal PACE trial (NCT01207440). Longer follow-up of PACE revealed a higher cumulative incidence of arterial occlusive events than originally reported at the time of approval. Modeling the data from PACE suggests that there is a dose-effect relationship with both adverse events (AEs) and response rates, and that lower doses may mitigate cardiovascular risk while maintaining efficacy....
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Valentin Garc ía Gutierrez, Jorge Cortes, Michael Deininger, Maria Baer, Vamsi Kota, Luke Akard, Charles Chuah, Agnes Guerci-Bresler, Juan Luis Steegmann, Juan-Carlos Hernández Boluda, Stephanie Lustgarten, Frank Haluska, Heinrich Farin Source Type: research

Detection of BCR-ABL Kinase Domain Mutations in Chronic Myeloid Leukemia Patients
The patient with chronic myeloid leukemia (CML) is treated successfully with tirosin kinase inhibitors (TKIs). Worldwide there are a 20 to 30% of patients, who have resistance to the treatment. The first cause of TKIs resistance is the presence of BCR-ABL kinase domain mutations. In Guatemalan population of around 35% of CML, patients are resistant to TKIs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Nancy Escobar, Mariana Herrera, Luisa Rosales, Silvana Torselli, Julio Caceres, Mauricio Villegas, Mariela Guerra, Nely Marroquin, Claudia Osorio, Vanessa Zamora, Darwin Alvarez, Luis Alvarez, Claudia Carranza Source Type: research

OPTIC-2L: a Superiority Trial of Two Lower Doses of Ponatinib Versus Standard Dose Nilotinib in Second-Line Chronic Phase CML
Up to half of chronic-phase chronic myeloid leukemia (CP-CML) patients with first-line tyrosine kinase inhibitor (TKI) imatinib treatment become resistant or intolerant. A sizable portion of patients (38-49%) do not achieve major cytogenetic response (MCyR) with second-line treatment with dasatinib, nilotinib, or bosutinib. None of these agents have activity against all known kinase domain mutations and all are refractory to the T315I mutation. Ponatinib (45 mg daily), a potent pan-BCR-ABL TKI, demonstrated strong efficacy among a small cohort of second-line CP-CML patients, including those with the T315I mutation, in the ...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Jeffrey Lipton, Andreas Hochhaus, Angelo Carella, Marianne Severinsen, Peter te Boekhorst, Antonio Almeida, Charles Chuah, Violaine Havelange, Gabriela Baerlocher, Stephanie Lustgarten, Heinrich Farin, Frank Haluska Source Type: research

Impact of Landmark Responses on 3-Year Outcomes in CP-CML Patients in the Ponatinib PACE Trial
Ponatinib is a potent oral tyrosine kinase inhibitor (TKI) approved for patients with refractory CML/Ph+ ALL, or with T315I. In first- and second-line settings with other TKIs, landmark responses have been correlated with positive long-term outcomes; data are limited for heavily pretreated populations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Moshe Talpaz, Martin M üller, Michele Baccarani, Michael Deininger, François Guilhot, Andreas Hochhaus, Timothy Hughes, Neil Shah, Stephanie Lustgarten, Victor Rivera, Tim Clackson, Frank Haluska, Jorge Cortes Source Type: research

Dropled Digital PCR May Have a Prognostic Value for Predicting Relapse after Imatinib Discontinuation
Nowadays it is possible to safely discontinue imatinib but it is still not clear which patient (pt) will relapse. High sensitivity techniques like droplet digital (dd) PCR may help to discriminate pts who still present a significant amount of disease despite being in MR4 by standard RT-PCR. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Carmen Fava, Marta Varotto, Paola Berchialla, Enrico Gottardi, Filomena Daraio, Roberta Lorenzatti, Emilia Giugliano, Davide Barberio, Alessandra Iurlo, Ester Orlandi, Patrizia Pregno, Dario Ferrero, Giovanna Rege-Cambrin, Giuseppe Saglio Source Type: research

Rapid Achievement of MR4.5 after Switching from Imatinib to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal
ENESTgoal is an ongoing phase 2 study of treatment-free remission (TFR) after second-line nilotinib in patients who achieved major molecular response (MMR) but not MR4.5 on imatinib. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Ellen Ritchie, Michael Deininger, Harry Erba, Michael Savona, Carole Paley, Ilva Dautaj, Michael Mauro Source Type: research

Inhibition of B-Catenin and Bcr-Abl Tyrosine Kinase Synergistically Targets Blast Crisis CML Cells and Stem/Progenitor Cells In Vitro and In Vivo
Bcr-Abl tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment. However, these agents have limited activity against blast crisis (BC) CML, and are unable to eliminate leukemia stem cells. Interestingly, β-catenin, required for the maintenance of CML stem cells is constitutively activated in BC CML, which reputedly drives BC self-renewal capacity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Bing Carter, Hongsheng Zhou, Po Mak, Hong Mu, Duncan Mak, Zhihong Zeng, Jorge Cortes, Michael Andreeff Source Type: research

A Nationwide Observational Study of Ponatinib in CML Patients Outside of Clinical Trials- The Israeli Experience
The oral tyrosine kinase inhibitor (TKI) ponatinib is indicated for T315I positive CML patients and for patients who cannot be prescribed any other TKI. Currently, there is little real-life information regarding the use of ponatinib outside of clinical trials. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Irina Amiati, Adi Shacham-Abulafia, Roy Ratzon, Pia Raanani, David Lavie, Yulia Volchek, Ron Ram, Ilana Hellmann, Liat Shargian, Anna Gourevietch, Evgeni Chubar, Uri Rozovski Source Type: research

Treatment-Free Remission (TFR) Following Frontline or Second-Line Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTfreedom and ENESTop
TFR (ie, stopping tyrosine kinase inhibitor [TKI] therapy following achievement of sustained deep molecular response [DMR]) is an emerging treatment goal for patients with CML-CP. TFR was first demonstrated in the Stop Imatinib (STIM) trial ( ≈40% of patients maintained DMR 1 year after stopping long-term imatinib), and trials investigating TFR following second-generation TKIs are ongoing. The ENEST TFR trial program is specifically evaluating TFR following nilotinib treatment; primary results from ENESTfreedom (TFR after frontline nil otinib) and ENESTop (TFR after second-line nilotinib) were recently presented. (So...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Fran çois-Xavier Mahon, Andreas Hochhaus, Timothy Hughes, Sikander Ailawadhi, Jeffrey Lipton, Johannes Wolff, Giuseppe Saglio Source Type: research

Indications and Outcomes of Allogeneic Stem Cell Transplant for Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors
The need for an allogeneic stem cell transplant (HCT) for management of CML has decreased in the TKI era, yet in the setting of resistance or intolerance to TKIS, HCT may be the only remaining treatment option. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Kendra Sweet, Josephine Emole, Asmita Mishra, Javier Pinilla-Ibarz Source Type: research

The Prognostic Value of the Myeloid-Mediated Immunosuppression Marker Arginase-1 in Classic Hodgkin Lymphoma
We previously showed that myeloid-derived suppressor cells (MDSC) have prognostic meaning in classic Hodgkin Lymphoma (cHL), but their assay in peripheral blood is barely reproducible (Romano, BJH, 2015). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Alessandra Romano, Nunziatina Parrinello, Calogero Vetro, Daniele Tibullo, Cesarina Giallongo, Piera La Cava, Annalisa Chiarenza, Giovanna Motta, Anastasia Caruso, Loredana Villari, Claudio Tripodo, Sebastiano Cosentino, Massimo Ippolito, Ugo Consoli, And Tags: Hodgkin Lymphoma Source Type: research

Survival Pattern of Hodgkin's Lymphoma Patients in the Last 25 Years in Lebanon
After the emergence of combination chemotherapy in 1960s, survival of Hodgkin's lymphoma (HL) patients has dramatically improved worldwide. We lack studies that document the favorable evolution of survival regarding this disease in Lebanon. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Marcel Massoud, Fouad Kerbage, Joseph Nehme, Riwa Sakr, Layale Rached, Jean Zeghondy, Fadi Nasr, Georges Chahine Source Type: research

Real Life Experience for Integration of PET-CT in the Treatment of HL in Lebanon
Hodgkin Lymphoma is a highly curable disease; more than 90% of patients achieve long term survival. PET-CT has played a major role in the evaluation of both disease staging and response, it has become an essential component in the tailoring of the treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Riwa Sakr, Marcel Massoud, Fouad Kerbage, Layale Rached, Jean Zeghondy, Fadi Nasr, Georges Chahine Source Type: research

Post Transplant Brentuximab Maintenance Appears more Effective than Post Transplant Salvage Brentuximab for Relapsed /Refractory Hodgkin Lymphoma
Brentuximab Vedotin (BV) is a chimeric anti CD30 IgG1 antibody, conjugated to synthetic antitubulin momomethyl auristatin. BV is approved for the treatment of classical HL in relapse either after autologous stem cell transplantation (ASCT) or after two lines of combination chemotherapy in transplant ineligible patients. The AETHERA trial revealed increased PFS when BV is used as maintenance therapy after ASCT. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Amanda Chidiac, Radwan Massoud, Mohamad Haidar, Ali Bazarbachi, Jean El Cheikh Source Type: research

Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL
Syncytial variant of nodular sclerosis HL (SV) is a well described pathologic entity characterized by prominent aggregates of Hodgkin/Reed Sternberg cells in nodules separated by fibrous collagen bands. Little is known regarding the clinical behavior of the SV. We systematically studied the clinical features and outcome of patients with SV and further compared them with patients with typical nodular sclerosis HL (t-NS). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Tarsheen Sethi, Van Nguyen, Shaoying Li, David Morgan, John Greer, Nishitha Reddy Source Type: research

High-Density Neutrophils are Immunosuppressive in Multiple Myeloma Due to Increased Arginase-1, Predictor of Short Progression Free Survival
In Multiple Myeloma (MM), granulocytic myeloid derived suppressor cells (G-MDSC) have a pivotal role in the interaction between the host immune system and plasma-cells (PC) proliferation. However, it is hard distinguishing G-MDSC from other neutrophil subpopulations, such as mature high-density neutrophils (HDN). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Alessandra Romano, Manteiga Jose, Vittorio Simeon, Nunziatina Parrinello, Cesarina Giallongo, Piera La Cava, Giuseppina Rizzo, Concetta Conticello, Maria Consoli, Daniele Tibullo, Lorenzo Canziani, Francesca Fontana, Pellegrino Musto, Simone Cenci, France Tags: Multiple Myeloma Source Type: research

Pegfilgrastim 6 mg versus 12 mg for Autologous Stem Cell Mobilization in Multiple Myeloma Patients
Pegfilgrastim (PEG) is a superior hematopoietic cell mobilizing agent in autologous stem cell transplant in Multiple Myeloma (MM) patients. While most institutions use PEG 12 mg, we have conducted a retrospective analysis comparing the performance of PEG 12 mg (pre change) and PEG 6 mg (post change) for mobilization of hematopoietic progenitor cells in patients with MM. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sara Matar, Mohammed Dany, Robert Stuart, Saurabh Chhabra Chhabra, Luciano Costa Source Type: research

VEGF, VEGFR2 and GSTM1 Polymorphisms in Outcome of Multiple Myeloma Patients in the Thalidomide Era
This study aimed to investigate the roles of VEGF c.-2595C>A (rs699947), c.-1154G>A (rs1570360), c.-634G>C (rs2010963), c.*237C>T (rs3025039), VEGFR2 c.-906T>C (rs2071559) and c.889G>A (rs2305948) SNPs, and GSTM1 andGSTT1 genes in outcome of MM patients treated with thalidomide-based regimen. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Angelo Brito, Leisa Lopes-Aguiar, Marcia Delamain, Gustavo Lourenco, Ericka Costa, Gislaine Oliveira, Jose Vassallo, Carmino de Souza, Carmen Lima Source Type: research

Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma
The revised International Staging System (R-ISS) was recently introduced in order to improve risk stratification over the widely used ISS. R-ISS incorporates, in addition to ISS, the presence of chromosomal abnormalities detected by iFISH (t(4;14), t(14;16) and del17p) and elevated serum lactate dehydrogenase. R-ISS formulation was based on a large dataset of selected patients who had participated in clinical trials and has not been validated in an independent cohort of unselected patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Maria Gavriatopoulou, Efstathios Kastritis, Evaggelos Terpos, Maria Roussou, Magdalini Migkou, Despoina Fotiou, Evaggelos Papaiakovou, Dimitrios Ziogas, Ioannis Panagiotidis, Meletios Dimopoulos Source Type: research

Daratumumab Yields Rapid Hematologic Responses in Patients with Heavily Pretreated, Relapsed AL Amyloidosis
Immunoglobulin light chain amyloidosis (AL) is a clonal plasma cell disorder in which patients (pts) have significant morbidity and mortality related to amyloid mediated organ dysfunction. Novel agent combinations yield high upfront hematologic response rates, but the majority of pts relapse. Response rates in the relapsed setting remain poor. Daratumumab is a monoclonal antibody targeted to CD38. There is strong rationale to believe it may have efficacy in other plasma cell disorders such as AL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Gregory Kaufman, Ronald Witteles, Mathew Wheeler, Patricia Ulloa, Marie Lugtu, Sally Arai, Richard Lafayette, Stanley Schrier, Michaela Liedtke Source Type: research

Newly Diagnosed Multiple Myeloma is Associated with Hypercoagulability and High Risk of VTE The ROADMAP Study
The optimization of venous thromboembolism (VTE) prevention, a significant cause of increased morbidity, in patients with multiple myeloma (MM) is an unmet need. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Despina Fotiou, Grigoris Gerotziafas, Flora Zagouri, Theodoros Sergentanis, Kimon Stamatelopoulos, Theodora Psaltopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios Dimopoulos Source Type: research

The Pathophysiologic Role of JunB in Multiple Myeloma Pathogenesis: Focus on Angiogenesis
This study aims to clarify the pathophysiologic role of JunB in multiple myeloma angiogenesis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Stefano Malvestiti, Hasan Bashari, Fengjuan Fan, Sonia Vallet, Klaus Podar, Dirk J äger Source Type: research

Antibacterial Prophylaxis Reduces the Risk of Bacteremia in Patients with Multiple Myeloma and Lymphoma Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplantation
Bacterial infections are a major cause of morbidity and mortality in patients undergoing autologous stem cell transplantation (ASCT). Whether these patients benefit from antibacterial prophylaxis is unclear and the few studies which addressed this issue are limited by small sample size. At our center, we stopped giving ciprofloxacin in 2012. This change in policy provided us the opportunity to study the potential benefit of prophylaxis in ASCT. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Liat Shargian-Alon, Iuliana Vaxman, Uri Rozvoski, Maya Moshe, Pia Raanani, Moshe Yeshurun Source Type: research

The Impact of Circulating Plasma Cells at Transplant on Survival in Multiple Myeloma in the Era of Novel Agents
The impact of circulating plasma cells (CPCs) detected by multiparameter flow cytometry (MFC) at transplant on survival has not been defined in the era of novel agents. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Rajshekhar Chakraborty, Eli Muchtar, Shaji Kumar, Francis Buadi, David Dingli, Angela Dispenzieri, Suzanne Hayman, William Hogan, Prashant Kapoor, Martha Lacy, Nelson Leung, Morie Gertz Source Type: research

A Pilot Study on the Efficacy of Lactobacillus Brevis CD2 Lozenges in Preventing Oral Mucositis by High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation
Treatment-induced oral mucositis (OM) is a pathological process characterized by mucosal damage, from mild inflammation to deep ulcerations and affecting one or more parts of the gastrointestinal tract as a consequence of chemotherapy and radiation therapy. The major complications in haematological malignancies patients (pts) submitted to HSCT are infections, in particular due to E.Coli, P. Aeruginosa and Candida. Treatment of OM is only palliative. Several studies showed the successful treatment of the symptoms associated to OM with the strain of Lactobacillus brevis, due to the process of microflora manipulation. (Source...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sabrina Giammarco, Patrizia Chiusolo, Alessia Di Giovanni, Elisabetta Metafuni, Simona Sica, Federica Iavarone, Federica Marini, Massimo Castagnola Source Type: research

Prospective Trial of Comparision Mobilization Regimens in Patients with Multiple Myeloma before Autologous SCT
Optimal mobilization protocol for AHSC is not determined yet. In our prospective trial we use three different regimes of HSC mobilization. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Dmitry Motorin, Diana Babenetskaya, Alexey Petrov, Renat Badaev, Natalia Ilyina, Tatiana Silina, Darina Zamoeva, Georgy Baratashvili, Yulia Alexeeva, Andrey Zaritskey Source Type: research

Retrospective Cohort Analysis Examining the Efficacy and Safety of (V)DTPACE in Newly Diagnosed and Relapsed/Refractory Myeloma Patients – the UK Experience
Multiple myeloma remains incurable in spite of advances in treatment. In UK, combination of dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide (DTPACE) continues to play a role in patients with relapsed/refractory multiple myeloma (RRMM), as bridge to transplant or for rapid tumor bulking. Recently, bortezomib has been included (VDTPACE), following favorable results from the TT3 study. However results outside the Arkansas group have been rarely reported. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Priya Sriskandarajah, Helen Jolly, Charlotte Pawlyn, Kabir Mohammed, Claire Dearden, Mike Potter, Faith Davies, Gareth Morgan, Kevin Boyd, Martin Kaiser Source Type: research

Systemic AL Amyloidosis Myopathy: Presentation, Diagnostic Pitfalls and Outcome
Amyloid myopathy is a rare syndrome with sparse data on its presentation and outcome. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Eli Muchtar, Daniele Derudas, Michelle Mauermann, Teerin Liewluck, Angela Dispenzieri, Shaji Kumar, David Dingli, Martha Lacy, Francis Buadi, Suzanne Hayman, Prashant Kapoor, Nelson Leung, Rajshekar Chakraborty, Wilson Gonsalves, Stephen Russell, John Lus Source Type: research

Clinical Features and Outcomes of Plasmacytoma: a National Cancer Database Study (2000 – 2011)
Most of the studies of plasmacytoma are derived from small, single tertiary institution experiences. There is a paucity of large studies to assess real-world outcomes and survival patterns in this disease within the community. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Gaurav Goyal, Wilson Gonsalves, Ronald Go Source Type: research

High Throughput Chemical Library  Screens Identify a Novel Small Molecule Checkpoint Inhibitor that Activates Anti-myeloma T Cells
Multiple myeloma (MM) remains an incurable plasma cell malignancy. Checkpoint inhibitors represent a revolutionary approach that empowers the immune system to defeat cancer. PD-L1 and PD-L2 expressed on tumor cells engage PD-1 on T cells to block antitumor responses. Here, we identified a novel small molecule PI3K/p110- δ inhibitor that downregulates PD-L1/PD-L2 on MM cells and enhances T cell anti-myeloma activity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: James J. Driscoll, Irim Aslam, Ehsan Malek Source Type: research

Identifying the Genomic Landscape of Pediatric Myelodysplastic Syndromes (MDS)
MDS is uncommon in children (incidence of ∼2 cases/million) and carries a poor prognosis. Much has been learned about adult MDS using high-throughput sequencing, which has identified recurrent mutations in genes that regulate epigenetics and RNA transcript splicing. Much less is understood about pediatric MDS, and many recurrent mutations found in adults are not common in children. Furthermore, the clinical presentation, bone marrow morphology, and cytogenetic abnormalities are also different when comparing adult and pediatric MDS, suggesting disparate underlying mechanisms. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Jason Schwartz, Michael Walsh, Jina Ma, Tami Lamprecht, Raul Ribeiro, Jeffery Klco Tags: Myelodysplastic Syndromes Source Type: research

Feasibility of Allogeneic Stem Cell Transplantation After Azacitidine in  Patients with High Risk Myelodysplastic Syndromes or Low-Blast Count Acute Myeloid Leukemias: the Experience of the BMT-AZA Multicenter Prospective Study
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative approach for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Since azacitidine approval for the treatment of high-risk MDS and low-blast count AML, patients experienced reduction of therapy-related complications and satisfactory overall response rate. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Maria Teresa Voso, Marianna Criscuolo, Giuseppe Leone, Alfonso Piciocchi, Luana Fianchi, Stella Santarone, Anna Candoni, Arianna Masciulli, Elisa Cerqui, Alfredo Molteni, Carlo Finelli, Matteo Parma, Antonella Poloni, Nicola Cascavilla, Francesco Spina, A Source Type: research

The Role of Hypomethylating Agents (Hma) in Early Myeloid Relapses After Allogenic Hematopoietic Stem Cell Transplant (HSCT)
To retrospectively analyze the outcome of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) early relapsing after HSCT. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: F élix López Cadenas, Ana Martín López, Javier Carrillo Checa, Oriana López Godino, Oscar Ferré, Luís García Martín, Estefanía Pérez López, Lourdes Vázquez López, María Díez-Campelo, Lucía López Corral, Maria Consuelo Del Cañizo Fernán Source Type: research

International Sentinel Site Surveillance of Patients with Transfusional Hemosiderosis Treated with Deferasirox in Actual Practice Setting
The oral iron chelator deferasirox is indicated for treatment of chronic iron overload (IOL) resulting from blood transfusions in patients aged ≥2 years. Multiple clinical studies have established the efficacy and safety of deferasirox in transfusion-dependent patients with IOL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Amal El-Beshlawy, Baba Inusa, David Beneitez, Blanca Xicoy, Maria Soledad Duran Nieto, Andreas Bruederle, Amin Azmon, Geralyn Gilotti, Mohsen Elalfy Source Type: research

Myelodysplastic Syndromes with Bone Marrow Fibrosis: a Distinct Entity
The WHO 2008 MDS classification recognizes MDS with fibrosis (MDS-F) as an unclassified subtype and there remains little data pertaining to the treatment and outcomes in the MDS-F. The primary objective of this study is to examine a large MDS population to determine the relationship between BMF and survival outcomes in the context of new risk stratification models. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Megan Melody, Najla Al Ali, Ling Zhan, Hanadi Ramadan, Eric Padron, David Sallman, Jeffery Lancet, Alan List, John Bennett, Rami Komrokji Source Type: research